Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Accounts Payable to Related Party (Details)

v3.25.4
Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Defined Benefit Plan Disclosure [Line Items]    
Beginning balance $ 1,183,000 $ 3,515,000
Invoices, net 743,000 2,335,000
Payments in cash (1,054,000) (3,857,000)
Payments in common stock, at fair value (810,000)
Payments in pre-funded warrants, at fair value (847,000)
Ending balance $ 25,000 $ 1,183,000